Showing results (421-430 of 552) with videos related to
Sort By:
Pageof 56
Journal of Drugs in Dermatology : JDD|January 6, 2026
Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United StatesKatrina Abuabara, Christopher G Bunick, Lara Wine Lee, et al.The Journal of Dermatological Treatment|March 12, 2026
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitisJonathan I Silverberg, Thomas Bieber, Kilian Eyerich, et al.Journal of the American Academy of Dermatology|March 6, 2020
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOSJonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, et al.The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2023
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trialEmma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi, et al.Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.Nature Communications|October 25, 2024
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I Silverberg, David Rosmarin, Raj Chovatiya, et al.Current Medical Research and Opinion|December 3, 2024
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD RegistryMichael A Haft, Keith D Knapp, Ami Claxton, et al.Dermatology and Therapy|August 7, 2024
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic DermatitisAndrew Blauvelt, Kilian Eyerich, Alan D Irvine, et al.The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.Pageof 56